Treatment of the patients with and without GVHD
| . | . | Patients with estensive cGVHD, 22 . | Patients without cGVHD, 17 . |
|---|---|---|---|
| ecGVHD prophylaxis | |||
| CsA + MTX | 37 | 22 | 15 |
| CsA + MMF | 1 | 0 | 1 |
| CsA + MTX + ATG | 1 | 0 | 1 |
| ecGVHD therapy | |||
| prednisone | 2 | ||
| prednisone + azathioprine | 1 | ||
| prednisone+ rituximab | 2 | ||
| CsA + prednisone | 3 | ||
| CsA + prednisone+ azathioprine | 8 | ||
| miscellaneous including ECP | 6 | ||
| ecGVHD targets | |||
| skin (generalized scleroderma) | 9 | ||
| skin-liver-sicca syndrome | 2 | ||
| skin-lung-sicca syndrome | 1 | ||
| sicca syndrome | 1 | ||
| skin-sicca syndrome | 4 | ||
| skin-lung | 5 |
| . | . | Patients with estensive cGVHD, 22 . | Patients without cGVHD, 17 . |
|---|---|---|---|
| ecGVHD prophylaxis | |||
| CsA + MTX | 37 | 22 | 15 |
| CsA + MMF | 1 | 0 | 1 |
| CsA + MTX + ATG | 1 | 0 | 1 |
| ecGVHD therapy | |||
| prednisone | 2 | ||
| prednisone + azathioprine | 1 | ||
| prednisone+ rituximab | 2 | ||
| CsA + prednisone | 3 | ||
| CsA + prednisone+ azathioprine | 8 | ||
| miscellaneous including ECP | 6 | ||
| ecGVHD targets | |||
| skin (generalized scleroderma) | 9 | ||
| skin-liver-sicca syndrome | 2 | ||
| skin-lung-sicca syndrome | 1 | ||
| sicca syndrome | 1 | ||
| skin-sicca syndrome | 4 | ||
| skin-lung | 5 |
MTX indicates methotrexate; MMF, mycophenolate mofetil; CsA, cyclosporin A; ATG, antithymocyte globulin; and ECP, photopheresis